Finding inhibitors for PCSK9 using computational methods.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key targets for atherosclerosis drug development as its binding with low-density lipoprotein receptor leads to atherosclerosis. The protein-ligand interaction helps to understand the actual mechanism for the pharmacological action....
Saved in:
Main Authors: | Rida Zainab, Afshan Kaleem, Michał B Ponczek, Roheena Abdullah, Mehwish Iqtedar, Daniel C Hoessli |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c99e97c78a2c47ea9969b0b623c9f424 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020) -
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.
by: Rhogerry Deshycka, et al.
Published: (2021) -
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
by: Rhogerry Deshycka, et al.
Published: (2021) -
Current Evidence and Future Directions of PCSK9 Inhibition
by: Jiaqian Xu, et al.
Published: (2021) -
Effects of immunisation against PCSK9 in mice bearing melanoma
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019)